WO1997040848A1 - Use of prolactin as a tgf-beta antagonist - Google Patents
Use of prolactin as a tgf-beta antagonist Download PDFInfo
- Publication number
- WO1997040848A1 WO1997040848A1 PCT/US1997/007310 US9707310W WO9740848A1 WO 1997040848 A1 WO1997040848 A1 WO 1997040848A1 US 9707310 W US9707310 W US 9707310W WO 9740848 A1 WO9740848 A1 WO 9740848A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tgf
- prolactin
- cells
- cell
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97921467A EP0921809A4 (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a tgf-beta antagonist |
AU27496/97A AU2749697A (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a tgf-beta antagonist |
JP09539206A JP2000510112A (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a TGF-β antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1649296P | 1996-04-30 | 1996-04-30 | |
US60/016,492 | 1996-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997040848A1 true WO1997040848A1 (en) | 1997-11-06 |
Family
ID=21777407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/007310 WO1997040848A1 (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a tgf-beta antagonist |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0921809A4 (en) |
JP (1) | JP2000510112A (en) |
AU (1) | AU2749697A (en) |
CA (1) | CA2232682A1 (en) |
WO (1) | WO1997040848A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
WO2012090997A1 (en) | 2010-12-27 | 2012-07-05 | 京都府公立大学法人 | iPS CELLS AND METHOD FOR GENERATING SAME |
WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
WO2013100208A1 (en) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | Normalization of culture of corneal endothelial cells |
US8642034B2 (en) | 2006-10-03 | 2014-02-04 | Genzyme Corporation | Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
EP2835053A1 (en) | 2010-03-12 | 2015-02-11 | Genzyme Corporation | Combination therapy for treating breast cancer |
EP2862867A2 (en) | 2005-10-25 | 2015-04-22 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
WO2015064768A1 (en) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
US9468612B2 (en) | 2011-10-26 | 2016-10-18 | Seattle Children's Hospital | Cysteamine in the treatment of fibrotic disease |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU700104B2 (en) * | 1994-02-14 | 1998-12-24 | Genzyme Corporation | Prolactin as a vaccine adjuvant |
-
1997
- 1997-04-30 CA CA002232682A patent/CA2232682A1/en not_active Abandoned
- 1997-04-30 JP JP09539206A patent/JP2000510112A/en active Pending
- 1997-04-30 WO PCT/US1997/007310 patent/WO1997040848A1/en not_active Application Discontinuation
- 1997-04-30 AU AU27496/97A patent/AU2749697A/en not_active Abandoned
- 1997-04-30 EP EP97921467A patent/EP0921809A4/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
RAYHEL E J, ET AL.: "INHIBITION OF NB2 T-LYMPHOMA CELL GROWTH BY TRANSFORMING GROWTH FACTOR-BETA", BIOCHEMICAL JOURNAL, PORTLAND PRESS LTD., GB, vol. 253, no. 01, 1 July 1988 (1988-07-01), GB, pages 295 - 298, XP002948719, ISSN: 0264-6021 * |
See also references of EP0921809A4 * |
WANG Y-F, WALKER A M: "DEPHOSPHORYLATION OF STANDARD PROLACTIN PRODUCES A MORE BIOLOGICALLY ACTIVE MOLECULE: EVIDENCE FOR ANTAGONISM BETWEEN NONPHOSPHORYLATED AND PHOSPHORYLATED PROLACTIN IN THE STIMULATION OF NB2 CELL PROLIFERATION", ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 133, no. 05, 1 January 1993 (1993-01-01), US, pages 2156 - 2160, XP001016118, ISSN: 0013-7227, DOI: 10.1210/en.133.5.2156 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2862867A2 (en) | 2005-10-25 | 2015-04-22 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
EP2918288A1 (en) | 2006-10-03 | 2015-09-16 | Genzyme Corporation | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
US8642034B2 (en) | 2006-10-03 | 2014-02-04 | Genzyme Corporation | Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
EP3254696A1 (en) | 2006-10-03 | 2017-12-13 | Genzyme Corporation | Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
EP2835053A1 (en) | 2010-03-12 | 2015-02-11 | Genzyme Corporation | Combination therapy for treating breast cancer |
EP3406141A1 (en) | 2010-03-12 | 2018-11-28 | Genzyme Corporation | Combination therapy for treating cancer |
WO2012090997A1 (en) | 2010-12-27 | 2012-07-05 | 京都府公立大学法人 | iPS CELLS AND METHOD FOR GENERATING SAME |
WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
US9468612B2 (en) | 2011-10-26 | 2016-10-18 | Seattle Children's Hospital | Cysteamine in the treatment of fibrotic disease |
US9925154B2 (en) | 2011-10-26 | 2018-03-27 | Seattle Children's Hospital | Cysteamine in the treatment of fibrotic disease |
WO2013100208A1 (en) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | Normalization of culture of corneal endothelial cells |
EP3553169A1 (en) | 2011-12-28 | 2019-10-16 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
WO2015064768A1 (en) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
EP3804760A1 (en) | 2013-10-31 | 2021-04-14 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Also Published As
Publication number | Publication date |
---|---|
EP0921809A1 (en) | 1999-06-16 |
JP2000510112A (en) | 2000-08-08 |
CA2232682A1 (en) | 1997-11-06 |
AU2749697A (en) | 1997-11-19 |
EP0921809A4 (en) | 2001-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Massague | The transforming growth factor-beta family | |
Schmid et al. | Differential expression of TGF β 1, β 2 and β 3 genes during mouse embryogenesis | |
Cooper et al. | Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta | |
Roberts et al. | Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. | |
Ruscetti et al. | Transforming growth factor-β and the immune system | |
US5612211A (en) | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors | |
D'Amore | Modes of FGF release in vivo and in vitro | |
Miyazono et al. | Platelet-derived growth factors | |
Gospodarowicz | Growth factors and their action in vivo and in vitro | |
US5436228A (en) | Chemotactic wound healing peptides | |
JP2007209349A (en) | Novel neurotrophic factor | |
CA2078547A1 (en) | Method of predisposing mammals to accelerated tissue repair | |
Hou et al. | Astrogliosis in culture. IV. Effects of basic fibroblast growth factor | |
US6749847B2 (en) | Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor | |
Kibbey et al. | Laminin SIKVAV peptide‐induced angiogenesis in vivo is potentiated by neutrophils | |
Yang et al. | Recombinant PDGF enhances megakaryocytopoiesis in vitro | |
Yamada et al. | Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours | |
US20050032697A1 (en) | Heparin binding VEGFR-3 ligands | |
EP0921809A1 (en) | Use of prolactin as a tgf-beta antagonist | |
Gribi et al. | Expression of activin A in inflammatory arthropathies | |
US5824647A (en) | Chemotactic wound healing peptides | |
Rico-Vargas et al. | c-kit expression by B cell precursors in mouse bone marrow. Stimulation of B cell genesis by in vivo treatment with anti-c-kit antibody. | |
US20020193301A1 (en) | TGF-alpha polypeptides, functional fragments and methods of use therefor | |
WO1991018620A1 (en) | Stimulation of bone marrow stromal and progenitor cells | |
Clark et al. | Transforming growth factor-β-like activity in tumors of the central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2232682 Country of ref document: CA Ref country code: CA Ref document number: 2232682 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/004640 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997921467 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997921467 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997921467 Country of ref document: EP |